ketoconazole has been researched along with nifedipine in 52 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (7.69) | 18.2507 |
| 2000's | 21 (40.38) | 29.6817 |
| 2010's | 26 (50.00) | 24.3611 |
| 2020's | 1 (1.92) | 2.80 |
| Authors | Studies |
|---|---|
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Jang, S; Jung, D; Lee, JW; Lee, S; Min, KH; Song, J | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Keserü, GM | 1 |
| Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Jia, L; Sun, H | 1 |
| Pratim Roy, P; Roy, K | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Sen, S; Sinha, N | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bakmiwewa, SM; Ball, HJ; Fatokun, AA; Hunt, NH; Payne, RJ; Tran, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Bron, S; Chambon, M; Colau, D; Majjigapu, SR; Michielin, O; Pilotte, L; Röhrig, UF; Turcatti, G; Van den Eynde, BJ; Vogel, P; Zoete, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Budriesi, R; Carosati, E; Chiarini, A; Chiu, FC; Cosimelli, B; Frosini, M; Fusi, F; Ioan, P; Katneni, K; Matucci, R; Micucci, M; Saponara, S; Severi, E; Spinelli, D | 1 |
| Ring, BJ; Wrighton, SA | 1 |
| Castagnoli, N; Fukui, M; Igarashi, K; Kasuya, F; Usuki, E | 1 |
| Hiroki, S; Shimada, T; Urano, T; Yamazaki, H | 1 |
| Ishizaki, T; Zhao, XJ | 1 |
| Fowler, SM; Friedberg, T; Pritchard, MP; Riley, RJ; Sutcliffe, MJ; Wolf, CR | 1 |
| Kayaba, H; Khalil, WF; Kishimoto, S; Kokue, E; Kuroha, M; Shimoda, M | 1 |
| Agúndez, JA; García-Gamito, FJ; García-Martín, E; Martínez, C; Pizarro, RM | 1 |
| Greenblatt, DJ; Patki, KC; Von Moltke, LL | 1 |
| Amano, A; Kamisaki, Y; Kato, T; Morisaki, I | 1 |
| Marks, B; Raucy, J; Trubetskoy, O; Yueh, MF; Zielinski, T | 1 |
| Booth-Genthe, C; Carr, B; Fang, Y; Lu, P; Norcross, R; Rodrigues, AD; Rushmore, T; Shou, M | 1 |
| Azuma, J; Hou, XL; Kinoshita, N; Komatsu, K; Qiu, F; Takahashi, K; Tanaka, K | 1 |
| Bhugra, C; Krill, SL; Pikal, MJ; Shmeis, R | 1 |
| Iwasaki, K | 1 |
| Ando, H; Araki, N; Enosawa, S; Fujimura, A; Hasegawa, G; Nagai, H; Omasa, T; Tsuruoka, S; Wang, N; Yanagihara, H | 1 |
| Alonzo, DE; Bates, S; Ivanisevic, I; Rumondor, AC; Taylor, LS | 1 |
| Court, MH; Duan, SX; Greenblatt, DJ; Harmatz, JS; Parent, SJ; Venkatakrishnan, K; von Moltke, LL; Zhao, Y | 1 |
| Annes, WF; Ayan-Oshodi, MA; Brown, T; de la Peña, A; Friedrich, S; Hall, SD; Lowe, SL; Willis, BA; Wise, SD; Zhang, W | 1 |
| Araki, N; Enosawa, S; Fujimura, A; Hasegawa, G; Omasa, T; Tsuruoka, S; Yamazoe, Y; Yanagihara, H | 1 |
| Choi, DH; Choi, JS; Lee, CK | 1 |
| Azuaje, J; Gomez-Amoza, JL; Martinez-Pacheco, R; Raviña-Eirin, E; Sotelo, E | 1 |
| Amano, N; Hirabayashi, H; Iwasaki, S | 1 |
| Kondo, S; Miyake, M | 1 |
3 review(s) available for ketoconazole and nifedipine
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics.
Topics: Biotransformation; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Enzyme Inhibitors; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Ketoconazole; Molecular Structure; Nifedipine; Polymorphism, Single Nucleotide; Tacrolimus | 2007 |
1 trial(s) available for ketoconazole and nifedipine
| Article | Year |
|---|---|
The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Topics: Administration, Oral; Adult; Aged; Alanine; Amyloid Precursor Protein Secretases; Area Under Curve; Azepines; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Half-Life; Hepatocytes; Humans; Hydroxylation; Ketoconazole; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Models, Biological; Nifedipine; Testosterone; Young Adult | 2012 |
48 other study(ies) available for ketoconazole and nifedipine
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Click Chemistry; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Structure; Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2019 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Topics: Algorithms; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Factor Analysis, Statistical; Least-Squares Analysis; Linear Models; Models, Molecular; Neural Networks, Computer; Quantitative Structure-Activity Relationship; Reproducibility of Results | 2009 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Topics: Animals; Dose-Response Relationship, Drug; Enzyme Inhibitors; HEK293 Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Substrate Specificity | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Topics: Animals; Antifungal Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Molecular Dynamics Simulation; Molecular Structure; Structure-Activity Relationship | 2014 |
Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.
Topics: Animals; Cells, Cultured; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Guinea Pigs; Heart Atria; Humans; Male; Microsomes, Liver; Myocytes, Cardiac; Oxadiazoles; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiazines; Vasodilator Agents | 2016 |
Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.
Topics: Chromatography, High Pressure Liquid; Cimetidine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Erythromycin; Humans; In Vitro Techniques; Ketoconazole; Microsomes, Liver; Midazolam; Nifedipine; Nizatidine | 1994 |
Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP.
Topics: Animals; Antibodies; Antipsychotic Agents; Biotransformation; Brain; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Haloperidol; Injections, Intraperitoneal; Ketoconazole; Male; Microsomes, Liver; Mitochondria; Mixed Function Oxygenases; Nifedipine; Pyridinium Compounds; Rats; Rats, Sprague-Dawley | 1995 |
Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes.
Topics: Animals; Anti-Bacterial Agents; Catalysis; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Erythromycin; Humans; Ketoconazole; Male; Microsomes, Liver; Mixed Function Oxygenases; Nifedipine; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Roxithromycin; Testosterone; Troleandomycin | 1996 |
Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.
Topics: Anti-Infective Agents; Antimalarials; Chromatography; Cytochrome P-450 Enzyme System; Doxycycline; Drug Interactions; Erythromycin; Humans; Hydroxylation; Ketoconazole; Microsomes, Liver; Nifedipine; Omeprazole; Primaquine; Quinine; Tetracycline; Troleandomycin | 1997 |
Amino acid 305 determines catalytic center accessibility in CYP3A4.
Topics: Alanine; Amino Acid Substitution; Aryl Hydrocarbon Hydroxylases; Binding Sites; Catalysis; Clotrimazole; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diazepam; Econazole; Erythromycin; Humans; Imidazoles; Ketoconazole; Kinetics; Miconazole; Mixed Function Oxygenases; Multienzyme Complexes; Mutation; Nifedipine; Oxidoreductases, N-Demethylating; Substrate Specificity; Testosterone | 2000 |
Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs.
Topics: Administration, Oral; Algorithms; Animals; Antifungal Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Calcium Channel Blockers; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dogs; Drug Interactions; Enzyme Inhibitors; Half-Life; Injections, Intravenous; Intestinal Mucosa; Ketoconazole; Liver; Male; Nifedipine; Oxidoreductases, N-Demethylating; Tablets | 2002 |
Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Colon; Colorectal Neoplasms; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Ketoconazole; Male; Microsomes, Liver; Middle Aged; Mutation; Nifedipine; Oxidoreductases, N-Demethylating; Paclitaxel; Rectum | 2002 |
In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Ketoconazole; Microsomes, Liver; Midazolam; Nifedipine; Recombinant Proteins; Testosterone; Triazolam | 2003 |
Enhancement of nifedipine-induced gingival overgrowth by concomitant ketoconazole in rats.
Topics: Animals; Antifungal Agents; Calcium Channel Blockers; Drug Synergism; Gingival Overgrowth; Ketoconazole; Male; Nifedipine; Rats; Rats, Inbred F344 | 2005 |
A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Chromans; Clotrimazole; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Dimethyl Sulfoxide; Enhancer Elements, Genetic; Enzyme Induction; Genes, Reporter; Genes, Synthetic; Humans; Ketoconazole; Liver Neoplasms; Lovastatin; Luciferases; Mifepristone; Neoplasm Proteins; Nifedipine; Omeprazole; Paclitaxel; Phenytoin; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Recombinant Fusion Proteins; Rifampin; Thiazolidinediones; Transcription, Genetic; Troglitazone; Troleandomycin | 2005 |
Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes.
Topics: Amino Acid Sequence; Animals; Baculoviridae; Base Sequence; Blotting, Western; Cell Line; Cloning, Molecular; Coumarins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Humans; Ketoconazole; Kinetics; Liver; Macaca mulatta; Microsomes, Liver; Midazolam; Molecular Sequence Data; Nifedipine; Recombinant Proteins; Sequence Analysis, DNA; Spodoptera; Substrate Specificity; Testosterone | 2006 |
Possible inhibitory mechanism of Curcuma drugs on CYP3A4 in 1alpha,25 dihydroxyvitamin D3 treated Caco-2 cells.
Topics: Caco-2 Cells; Calcitriol; Cell Survival; Curcuma; Curcumin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Enzyme Inhibitors; Herb-Drug Interactions; Humans; Hydroxylation; Inhibitory Concentration 50; Intestinal Mucosa; Ketoconazole; Nifedipine; Oxidation-Reduction; Plant Extracts; Rhizome; Rifampin; RNA, Messenger; Testosterone | 2007 |
Prediction of onset of crystallization from experimental relaxation times. II. Comparison between predicted and experimental onset times.
Topics: Algorithms; Calorimetry; Chemical Phenomena; Chemistry, Physical; Crystallization; Electrochemistry; Forecasting; Hydrogen Bonding; Indomethacin; Ketoconazole; Microscopy, Polarization; Models, Chemical; Models, Statistical; Nifedipine; Temperature; Thermodynamics | 2008 |
Human CYP3A4-introduced HepG2 cells: in vitro screening system of new chemicals for the evaluation of CYP3A4-inhibiting activity.
Topics: Ammonia; Animals; Atorvastatin; Cell Line, Tumor; Cricetinae; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glutamate-Ammonia Ligase; Heptanoic Acids; Humans; Ketoconazole; Lidocaine; Nifedipine; Pyrroles | 2008 |
Evaluation of drug-polymer miscibility in amorphous solid dispersion systems.
Topics: Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Crystallization; Felodipine; Ketoconazole; Models, Biological; Nifedipine; Polymers; Powders; Pyrrolidinones; Solubility; Thermodynamics; Water; X-Ray Diffraction | 2009 |
Mechanism of cytochrome P450-3A inhibition by ketoconazole.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Humans; Inhibitory Concentration 50; Ketoconazole; Male; Microsomes, Liver; Midazolam; Middle Aged; Nifedipine; Testosterone; Triazolam; Young Adult | 2011 |
Inhibition of CYP3A4 by 6',7'-dihydroxybergamottin in human CYP3A4 over-expressed hepG2 cells.
Topics: Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Food-Drug Interactions; Furocoumarins; Hep G2 Cells; Humans; Ketoconazole; Models, Biological; NADPH-Ferrihemoprotein Reductase; Nifedipine; Plant Extracts; RNA, Messenger | 2012 |
Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
Topics: Animals; Antifungal Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Calcium Channel Blockers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Fluorescent Dyes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ketoconazole; Male; Nifedipine; Rats; Rats, Sprague-Dawley; Rhodamine 123 | 2015 |
Drug structural features affect drug delivery from hyperbranched polyesteramide hot melt extrudates.
Topics: Amides; Chemistry, Pharmaceutical; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Liberation; Hot Temperature; Ketoconazole; Nifedipine; Pharmaceutical Preparations; Polyesters; Polymers; Solubility | 2016 |
Quantitative prediction of the extent of drug-drug interaction using a physiologically based pharmacokinetic model that includes inhibition of drug metabolism determined in cryopreserved hepatocytes.
Topics: Animals; Cryopreservation; Drug Interactions; Fluconazole; Hepatocytes; Ketoconazole; Microsomes, Liver; Nifedipine; Rats | 2018 |
Simultaneous Prediction of Intestinal Absorption and Metabolism Using the Mini-Ussing Chamber System.
Topics: Animals; Drug Delivery Systems; Intestinal Absorption; Intestinal Mucosa; Ketoconazole; Male; Midazolam; Nifedipine; Permeability; Pharmaceutical Preparations; Rats; Rats, Sprague-Dawley | 2019 |